{"id":1558,"date":"2010-06-16T17:05:34","date_gmt":"2010-06-16T21:05:34","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/%e2%80%a2-industry-employees-may-not-be-allowed-to-speak-at-the-aha%e2%80%a2-new-generation-stent-tested%e2%80%a2-bms-versus-des-for-stemi\/"},"modified":"2011-07-19T17:44:56","modified_gmt":"2011-07-19T21:44:56","slug":"%e2%80%a2-industry-employees-may-not-be-allowed-to-speak-at-the-aha%e2%80%a2-new-generation-stent-tested%e2%80%a2-bms-versus-des-for-stemi","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/06\/16\/%e2%80%a2-industry-employees-may-not-be-allowed-to-speak-at-the-aha%e2%80%a2-new-generation-stent-tested%e2%80%a2-bms-versus-des-for-stemi\/","title":{"rendered":"\u2022 Industry Employees May Not Be Allowed to Speak at the AHA<br \/>\u2022 New-Generation Stent Tested<br \/>\u2022 BMS Versus DES for STEMI"},"content":{"rendered":"<p><strong><\/strong><strong>Industry Employees May Not Be Allowed to Speak at the AHA:<\/strong>&nbsp;Industry employees may no longer be allowed to speak at the AHA scientific sessions and other CME-accredited events, according to&nbsp;<a href=\"http:\/\/www.jsonline.com\/features\/health\/96437904.html\">an article by John Fauber in the&nbsp;<em>Milwaukee Journal Sentinel<\/em>.<\/a>&nbsp;The ruling by the&nbsp;the Accreditation Council for Continuing Medical Education (ACCME) is being appealed by the AHA. The ruling was harshly condemned by NIH Director Francis Collins and other biomedical leaders.<br \/>\n<strong><br \/>\nNew-Generation Stent Tested:<\/strong>&nbsp;In the Resolute All Comers Trial, Patrick Serruys and colleagues randomized 2,292 PCI patients to either the Resolute zotarolimus-eluting stent or the Xience V everolimus-eluting stent. At 12 months, the rate of target lesion failure was 8.2% in the Resolute arm and 8.3% in the Xience V arm, thereby demonstrating noninferiority of the new Resolute stent (P&lt;0.001 for noninferiority). There were no significant differences in death from cardiac causes, MI, or revascularization between the two groups. Stent thrombosis occurred in 2.3% of the Resolute group compared to 1.5% of the Xience V group (P=0.17).<\/p>\n<p>A key feature of the trial is that it enrolled many patients excluded from previous stent trials, such as those with coexisting illnesses, acute MI, and multivessel disease. In their <a href=\"http:\/\/content.nejm.org\/cgi\/content\/full\/NEJMoa1004130\">report in the <em>New England Journal of Medicine<\/em><\/a><em><\/em>, the investigators conclude that &#8220;the new-generation zotarolimus-eluting stent was found to be as safe and effective as the everolimus-eluting stent in a group of patients for whom the procedure was considered to be predominantly off-label.&#8221;<br \/>\n<strong><br \/>\nBMS Versus DES for STEMI:<\/strong>&nbsp;Kaltoft and colleagues randomized 626 STEMI patients to a drug-eluting or a bare-metal stent. At 3 years, the rate of major adverse cardiac events was 11.5% in the DES group versus 18.2% in the BMS group (P=0.02). Although there was no difference in all-cause mortality, there was a significant difference in cardiac death (6.1% for DES vs. 1.9% for BMS, P=0.01). In their <a href=\"http:\/\/content.onlinejacc.org\/cgi\/content\/abstract\/j.jacc.2010.05.009v1\">report in the <em>Journal of the American College of Cardiology<\/em><\/a><em><\/em>, the investigators observe that &#8220;the very low cardiac mortality rate in our BMS group is hard to interpret, and the excess cardiac DES mortality should be interpreted accordingly and might have occurred by chance.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Industry Employees May Not Be Allowed to Speak at the AHA:&nbsp;Industry employees may no longer be allowed to speak at the AHA scientific sessions and other CME-accredited events, according to&nbsp;an article by John Fauber in the&nbsp;Milwaukee Journal Sentinel.&nbsp;The ruling by the&nbsp;the Accreditation Council for Continuing Medical Education (ACCME) is being appealed by the AHA. The [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1558","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1558"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1558\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}